<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04736589</url>
  </required_header>
  <id_info>
    <org_study_id>IR-1.1</org_study_id>
    <nct_id>NCT04736589</nct_id>
  </id_info>
  <brief_title>Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway</brief_title>
  <official_title>Efficacy and Safety of Inetetamab Combined With Rapamycin and Chemotherapy for HER2-positive Metastatic Breast Cancer Patients With Abnormal Activation of PI3K/Akt/mTOR Pathway After Progression on Trastuzumab.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center,randomized,phase 3 clinical trial. In the study, HER2-positive&#xD;
      metastatic breast cancer patients with abnormal activation of PI3K/Akt/mTOR pathway after&#xD;
      progression on trastuzumab are enrolled and randomized to receive the treatment of Inetetamab&#xD;
      plus Rapamycin plus chemotherapy or Pyrotinib plus chemotherapy.The study aimed to access the&#xD;
      efficacy and safety of Inetetamab combined with Rapamycin and chemotherapy in HER2-positive&#xD;
      metastatic breast cancer patients with abnormal activation of PI3K/Akt/mTOR pathway.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center,randomized,phase 3 clinical trial. In the study, HER2-positive&#xD;
      metastatic breast cancer patients with abnormal activation of PI3K/Akt/mTOR pathway after&#xD;
      progression on trastuzumab are enrolled and randomized to receive the treatment of Inetetamab&#xD;
      plus Rapamycin plus chemotherapy or Pyrotinib plus chemotherapy.The study aimed to access the&#xD;
      efficacy and safety of Inetetamab combined with Rapamycin and chemotherapy in HER2-positive&#xD;
      metastatic breast cancer patients with abnormal activation of PI3K/Akt/mTOR pathway after&#xD;
      progression on trastuzumab. The primary end point is Progressive-free Survival (PFS). The&#xD;
      secondary end points are Overall Response Rate (ORR),Overall Survival (OS),Clinical Benefit&#xD;
      Rate (CBR) and safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2, 2021</start_date>
  <completion_date type="Anticipated">February 2, 2027</completion_date>
  <primary_completion_date type="Anticipated">February 2, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progressive-free Survival (PFS)</measure>
    <time_frame>Estimated 24 months</time_frame>
    <description>Progressive-free Survival (PFS) is defined as the time from the date of randomization to the date of first radiologically documented tumor progression or death from any cause, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Estimated 24 months</time_frame>
    <description>Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT/MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival （OS）</measure>
    <time_frame>Estimated 48 months</time_frame>
    <description>Overall Survival （OS）is defined as the time from date of randomization to the date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR)</measure>
    <time_frame>Estimated 24 months</time_frame>
    <description>Clinical Benefit Rate (CBR) is defined as the percentage of participants whose best overall response, according to RECIST1.1, is either complete response (CR), a partial response (PR) or stable disease (SD) lasting for at least 24 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety(AEs and SAEs)</measure>
    <time_frame>From consent through 28 days following treatment completion</time_frame>
    <description>Adverse Events (AEs) and Serious Adverse Events (SAEs)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Inetetamab plus Rapamycin plus Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Inetetamab Initial dose of 8mg/kg, completed in 90 minutes IV infusion, and then 6 mg/kg over 30-90 minutes IV infusion every 3 weeks, until disease progression (PD) or other termination criteria are met;&#xD;
Drug: Rapamycin Oral 2mg, once a day;&#xD;
Drug: Chemotherapy drugs are not limited in this trial, please refer to their instructions for specific usage.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pyrotinib plus chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug:Pyrotinib Oral 400mg, once a day;&#xD;
Drug: Chemotherapy drugs are not limited in this trial, please refer to their instructions for specific usage.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inetetamab</intervention_name>
    <description>Initial dose of 8mg/kg, completed in 90 minutes IV infusion, and then 6 mg/kg over 30-90 minutes IV infusion every 3 weeks.</description>
    <arm_group_label>Inetetamab plus Rapamycin plus Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamycin</intervention_name>
    <description>Oral 2mg, once a day.</description>
    <arm_group_label>Inetetamab plus Rapamycin plus Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrotinib</intervention_name>
    <description>Oral 400mg, once a day.</description>
    <arm_group_label>Pyrotinib plus chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Chemotherapy drugs are not limited in this trial, please refer to their instructions for specific usage.</description>
    <arm_group_label>Inetetamab plus Rapamycin plus Chemotherapy</arm_group_label>
    <arm_group_label>Pyrotinib plus chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female, Aged &gt; 18;&#xD;
&#xD;
          2. HER2-positive breast cancer are defined as immunohistochemical (IHC) testing as +++,&#xD;
             or IHC++ with FISH testing of positive;&#xD;
&#xD;
          3. Histologically or cytologically confirmed invasive breast carcinoma with locally&#xD;
             recurrent or radiological evidence of metastatic disease.&#xD;
&#xD;
          4. Patients with HER2-positive metastatic breast cancer who have progressed disease after&#xD;
             trastuzumab treatment include the following four types of patients (Note: The&#xD;
             following patients are in a parallel relationship):&#xD;
&#xD;
               1. Patients with HER2-positive breast cancer who have progressed during adjuvant&#xD;
                  trastuzumab treatment after surgery; or&#xD;
&#xD;
               2. Patients with HER2-positive breast cancer who have relapsed or metastasized after&#xD;
                  receiving adjuvant trastuzumab therapy; or&#xD;
&#xD;
               3. HER2-positive recurrent or metastatic BC patients who have progressed after&#xD;
                  receiving at least 4 weeks of trastuzumab as first-line treatment ; or&#xD;
&#xD;
               4. HER2-positive metastatic BC patients who have never been treated have progressed&#xD;
                  after receiving at least 4 weeks of trastuzumab as first-line treatment.&#xD;
&#xD;
          5. Genetic testing shows that the PI3K/Akt/mTOR pathway related genes are mutated;&#xD;
&#xD;
          6. ECOG PS score ≤2, estimated survival time ≥6 months, and can be followed-up;&#xD;
&#xD;
          7. Patients with measurable disease as per RECIST 1.1 criteria;&#xD;
&#xD;
          8. Cardiopulmonary function is basically normal, LVEF≥50% within 4 weeks before starting&#xD;
             treatment;&#xD;
&#xD;
          9. An adequate liver function with the following definition:&#xD;
&#xD;
               1. Total bilirubin ≤ 1.5 times the upper limit of normal value. Patients with known&#xD;
                  Gibert's disease can be included in the group if combined bilirubin ≤ 1.5 times&#xD;
                  the upper limit of normal value;&#xD;
&#xD;
               2. AST and ALT ≤2.5 times the upper limit of the normal value; if there is liver&#xD;
                  metastasis, ≤5 times the upper limit of the normal value (the normal value is the&#xD;
                  normal value specified by this clinical trial center);&#xD;
&#xD;
         10. Have sufficient baseline hematology parameters, defined as follows:&#xD;
&#xD;
               1. ANC≥1.5 x 10^3 /μL;&#xD;
&#xD;
               2. Platelet count ≥100 x 10^3/μL, if it is 75-100 x 10^3/μL, it may be included in&#xD;
                  the group, as long as the doctors believe it can be included;&#xD;
&#xD;
               3. Hemoglobin ≥9 g/dL.&#xD;
&#xD;
         11. Coagulation Indicators: International normalized ratio (INR) and activated partial&#xD;
             thromboplastin time (aPTT) ≤ 1.5 times the upper limit of normal, unless drugs known&#xD;
             to change INR and aPTT are used;&#xD;
&#xD;
         12. No history of serious heart, kidney and other important organs and endocrine disease;&#xD;
&#xD;
         13. Female patients of childbearing age have a negative pregnancy test and voluntarily&#xD;
             take effective and reliable contraceptive measures;&#xD;
&#xD;
         14. The patients voluntarily signed an informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Anyone who has one of the following conditions cannot be selected for this trial:&#xD;
&#xD;
          1. Participated in other clinical trials within 4 weeks;&#xD;
&#xD;
          2. Have used mTOR inhibitors in the past;&#xD;
&#xD;
          3. Previous use of Pyrotinib in first-line treatment stage; previous use of lapatinib is&#xD;
             allowed;&#xD;
&#xD;
          4. Accompanied by immunosuppressant or chronic corticosteroid medication, or more than&#xD;
             25% bone marrow radiotherapy within 4 weeks;&#xD;
&#xD;
          5. Symptomatic CNS metastases or evidence of leptomeningeal disease;&#xD;
&#xD;
          6. Gastrointestinal dysfunction or gastrointestinal diseases (including active ulcers);&#xD;
&#xD;
          7. Hepatitis B or hepatitis C carriers, or other known chronic liver diseases; HIV&#xD;
             positive;&#xD;
&#xD;
          8. Known hypersensitivity to any study medication&#xD;
&#xD;
          9. Women during pregnancy or lactation;&#xD;
&#xD;
         10. Left ventricular ejection fraction &lt;50%; clinical manifestations of patients with&#xD;
             obvious arrhythmia, myocardial ischemia, severe atrioventricular block, cardiac&#xD;
             insufficiency, and severe valvular disease;&#xD;
&#xD;
         11. Any malignancy within 5 years prior to randomization, with the exception of adequately&#xD;
             treated in-situ carcinoma of the cervix uteri, basal or squamous cell carcinoma;&#xD;
&#xD;
         12. The researchers decide that any other medical, social or psychological conditions&#xD;
             which are inappropriate to participate in this trial.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fei Ma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fei Ma, MD</last_name>
    <phone>86-10-87788060</phone>
    <email>drmafei@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiuwen Guan, MD</last_name>
    <phone>86-10-87788060</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 31, 2021</study_first_submitted>
  <study_first_submitted_qc>January 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 3, 2021</study_first_posted>
  <last_update_submitted>January 31, 2021</last_update_submitted>
  <last_update_submitted_qc>January 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College</investigator_affiliation>
    <investigator_full_name>Fei Ma</investigator_full_name>
    <investigator_title>Associate director of the department of Medical Oncology in Cancer Hospital，Chinese Academy of Medical Sciences and Peking Union Medical College</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Inetetamab</keyword>
  <keyword>Rapamycin</keyword>
  <keyword>PI3K/Akt/mTOR pathway</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

